By Sahithya K · Reviewed by Divya Chandradhara · Published 6 November 2026
ICH GCP is the International Council for Harmonisation’s guideline for good clinical practice, the ethical and scientific quality standard for designing, conducting, recording and reporting clinical trials. Its current version, ICH E6(R3), was adopted in two stages: the principles and Annex 1 on 6 January 2025, and Annex 2 on 3 June 2026, which completed the revision. The principles, Annex 1 and Annex 2 are now published as one consolidated guideline. It replaces the 13 principles of E6(R2) with 11 principles and supporting annexes built around quality by design and risk-proportionate conduct.
What ICH E6(R3) is and what it replaced
ICH E6(R3), Guideline for Good Clinical Practice, was endorsed by the Regulatory Members of the ICH Assembly at Step 4 on 6 January 2025. It succeeds E6(R2), the integrated addendum adopted on 9 November 2016, which itself built on the original E6 of 1996. The E6(R3) guideline text is published by the ICH.
The guideline applies to interventional clinical trials of investigational products intended to be submitted to regulatory authorities. It says its principles may also apply to other interventional trials of investigational products that are not intended to support a marketing application, in line with local requirements.
How ICH E6(R3) is structured: principles, Annex 1, Annex 2 and appendices
ICH E6(R3) is made up of principles and annexes. The principles apply to every trial type and setting. Annex 1 explains how to apply them and is organised by party: the institutional review board or independent ethics committee, the investigator and the sponsor, with a new section on data governance shared by investigator and sponsor.
Annex 1 carries three appendices. Appendix A covers the Investigator’s Brochure, Appendix B the clinical trial protocol and protocol amendments and Appendix C the essential records for the conduct of a clinical trial. Annex 2, adopted on 3 June 2026, adds GCP considerations for trials with decentralised elements, pragmatic elements and real-world data sources. It builds on the principles and Annex 1 and is not intended to be read on its own; ICH now publishes all three as a single consolidated guideline. In the European Union, Annex 2 comes into effect on 15 January 2027.
The annexes are interpretive rather than rigid. E6(R3) states that different approaches to their provisions may be used, provided they are justified and achieve the purpose of the principles.
The 11 principles of ICH GCP E6(R3)
Table 1. The principles of ICH GCP in E6(R3)
| # | Principle, as E6(R3) states it | What it means in practice |
|---|---|---|
| 1 | Clinical trials should be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki | The rights, safety and well-being of participants prevail over the interests of science and society |
| 2 | Informed consent is an integral feature of the ethical conduct of a trial | Participation is voluntary and based on a consent process that leaves participants well informed |
| 3 | Clinical trials should be subject to an independent review by an IRB/IEC | The trial runs to the protocol the committee approved, with periodic review |
| 4 | Clinical trials should be scientifically sound for their intended purpose | Non-clinical and clinical information must be adequate to support the trial |
| 5 | Clinical trials should be designed and conducted by qualified individuals | Each person is qualified by education, training and experience for the task |
| 6 | Quality should be built into the scientific and operational design and conduct of clinical trials | Factors critical to quality are identified prospectively |
| 7 | Clinical trial processes, measures and approaches should be proportionate to the risks to participants and the importance of the data | Effort follows risk, without unnecessary burden on participants and investigators |
| 8 | Clinical trials should be described in a clear, concise, scientifically sound and operationally feasible protocol | The protocol and the plans that execute it are clear and workable |
| 9 | Clinical trials should generate reliable results | Systems, data and records are fit for purpose, traceable and retained |
| 10 | Roles and responsibilities in clinical trials should be clear and documented appropriately | Tasks may be transferred or delegated, but responsibility stays where it was |
| 11 | Investigational products should be manufactured to applicable GMP and managed to their specifications and the protocol | Product quality, blinding and labelling are maintained through to disposal |
Quality by design and critical to quality factors
Principle 6 makes quality something designed into a trial rather than checked afterwards. E6(R3) defines quality as fitness for purpose and requires the factors critical to the quality of the trial to be identified prospectively. These are the attributes fundamental to protecting participants and to the reliability and interpretability of the results.
Quality by design means focusing on those critical to quality factors to maximise the likelihood of the trial meeting its objectives. Principle 6 also requires strategies to avoid, detect, address and prevent recurrence of serious noncompliance with GCP, the protocol and applicable regulatory requirements.
Risk-proportionate trial conduct
Principle 7 requires trial processes, measures and approaches to be proportionate to the risks inherent in the trial and the importance of the information collected. Risks here include risks to participants’ rights, safety and well-being, and risks to the reliability of the results.
For trials in patients, the focus is on risks beyond those of usual medical care. Risks to critical to quality factors are managed proactively and adjusted when new issues arise. E6(R3) also says trial processes should avoid unnecessary complexity, procedures and data collection, and that the sponsor should not place unnecessary burden on participants and investigators.
Data governance and computerised systems
E6(R3) adds a section on data governance for investigators and sponsors, covering the data life cycle from capture through metadata and audit trails, review, correction, transfer, finalisation before analysis, retention and destruction. It also covers computerised systems, including training, security, validation, system release, system failure and user management.
The supporting principle is 9: computerised systems used in trials should be fit for purpose, for example through risk-based validation where appropriate, and records should be managed so that integrity and traceability are maintained and personal information is protected. The guideline is written to be media neutral, so the same expectations apply whether records are on paper or electronic. This is the part of E6(R3) that most affects clinical data management.
Sponsor responsibility when trial work is outsourced
Principle 10 states that the sponsor may transfer, and the investigator may delegate, tasks, duties or functions, but each retains overall responsibility for its activities. Where activities are transferred or delegated to service providers, responsibility for the conduct of the trial, including the quality and integrity of the data, stays with the sponsor or investigator.
Agreements must define roles, activities and responsibilities, and the sponsor or investigator must maintain appropriate oversight. For a sponsor choosing and working with a contract research organisation, this is the principle that decides how oversight is planned, documented and evidenced. Clinical quality assurance programmes are usually built around it.
What changed from ICH E6(R2) to E6(R3)
The main changes from E6(R2) to E6(R3) follow from the principles above:
The 13 principles of E6(R2) are restated as 11 principles, each with supporting provisions.
Quality by design and critical to quality factors are placed in the principles themselves.
Proportionality to risk runs through trial processes, monitoring and data collection.
Data governance and computerised systems have a dedicated section.
The guideline is media neutral and recognises digital health technologies, such as wearables and sensors, as legitimate trial tools.
Essential documents are now described as essential records, set out in Appendix C.
Trial design may draw on the perspectives of patients, their communities, patient advocacy groups and healthcare professionals.
Participant selection should be representative of the population the product is intended to benefit, while some trials, such as early phase and bioequivalence studies, may not need a heterogeneous population.
Transparency includes timely registration on public databases and public posting of results.
How ICH GCP applies to trials in India
In India the binding requirements for clinical trials are set by the New Drugs and Clinical Trials Rules, 2019. The Rules require trials to be conducted in accordance with the Good Clinical Practices Guidelines formulated by the Central Drugs Standard Control Organisation and adopted by the Drugs Technical Advisory Board. The Indian guidelines and ICH GCP share the same foundations, and trials run in India for multinational development programmes are routinely designed to meet both.
Where the two differ, the Indian requirement applies to the conduct of the trial in India. Examples include registration with the Clinical Trials Registry – India before enrolment, the reporting of serious adverse events within twenty-four hours and audio-video recording of consent for vulnerable subjects in trials of new chemical entities. Sponsors planning a trial can discuss both sets of requirements with BioAgile’s clinical trial services team.
Questions about ICH GCP E6(R3)
How many principles are there in ICH GCP?
ICH E6(R3), adopted on 6 January 2025, sets out 11 principles of good clinical practice, each with supporting provisions. The earlier version, E6(R2) of 2016, listed 13 principles. Pages that still refer to 13 principles of ICH GCP describe the superseded version rather than the current guideline.
When was ICH E6(R3) adopted?
The Regulatory Members of the ICH Assembly endorsed ICH E6(R3) under Step 4 of the ICH process on 6 January 2025. It had been released for public consultation at Step 2 on 19 May 2023. Each regulatory authority then implements the guideline according to its own procedures.
What is quality by design in ICH E6(R3)?
Quality by design means building quality into a trial’s scientific and operational design rather than checking for it afterwards. Under principle 6, the factors critical to quality, those fundamental to participant protection and to reliable, interpretable results, are identified prospectively and the trial is designed around protecting them.
Can a sponsor transfer its responsibilities to a CRO under ICH GCP?
A sponsor can transfer tasks, duties or functions to a service provider such as a contract research organisation, but it keeps overall responsibility. Principle 10 of E6(R3) states that responsibility for the conduct of the trial, including the quality and integrity of the data, stays with the sponsor, which must maintain appropriate oversight.
Is ICH GCP mandatory in India?
The NDCT Rules, 2019 require clinical trials in India to follow the Good Clinical Practices Guidelines formulated by CDSCO and adopted by the Drugs Technical Advisory Board. ICH GCP is the international standard those guidelines share their foundations with, and trials intended for submission in ICH regions are generally designed to meet both.
What are essential records in ICH E6(R3)?
Essential records are the records that permit evaluation of how a trial was conducted, whether the investigator and sponsor complied with GCP and how reliable the results are. E6(R3) uses the term in place of the earlier “essential documents” and sets them out in Appendix C. They are used in oversight, audit and inspection.
About this guide
This guide is based on ICH E6(R3), Guideline for Good Clinical Practice, the principles and Annex 1 adopted at Step 4 on 6 January 2025 and Annex 2 adopted on 3 June 2026, published as a consolidated guideline by the International Council for Harmonisation, and on the New Drugs and Clinical Trials Rules, 2019. It was written by Sahithya K and reviewed by Divya Chandradhara It states the position as at 6 November 2026 and is reviewed every six months and after any new annex or revision to the guideline.